Core Insights - Autonomix Medical, Inc. is set to present clinical feasibility and outcome data on a novel radiofrequency (RF) ablation technique for transvascular peripheral nerve neurolysis at the Cardiovascular Research Technologies (CRT) 2026 Meeting [1][2] Group 1: Presentation Details - The abstract titled "Novel Technique For Transvascular Peripheral Nerve Neurolysis Using Radiofrequency (RF) Ablation: Clinical Feasibility And Outcomes" will be presented during the Top Abstract Session on March 7, 2026 [2] - Dr. Nikola Cesarovic will deliver a six-minute presentation focusing on the clinical feasibility and early outcomes of the RF-based approach designed to selectively disrupt peripheral nerve activity [2][3] Group 2: Technology and Applications - Autonomix's technology aims to identify and target specific nerve signals, potentially offering greater therapeutic precision compared to conventional ablation techniques [2][3] - The company is initially developing this technology for pain treatment, particularly for pancreatic cancer, and believes it can address multiple indications across various medical fields, including cardiology and chronic pain management [4][5] Group 3: Company Overview - Autonomix Medical, Inc. is focused on advancing innovative technologies for diagnosing and treating diseases involving the nervous system, utilizing a catheter-based microchip sensing array [4] - The technology is investigational and has not yet received marketing clearance in the United States [5]